Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

194P - Fruquintinib in combination with S-1 for ESCC patients after first-line immunotherapy failure: Update of dose-finding results

Date

07 Dec 2024

Session

Poster Display session

Presenters

Ningning Li

Citation

Annals of Oncology (2024) 35 (suppl_4): S1450-S1504. 10.1016/annonc/annonc1688

Authors

N. Li, Y. Ge, X. Wang, W. Qiu, Z. Zhang, N. Zhou, L. Zhao

Author affiliations

  • Oncology Dept., PUMCH - Peking Union Medical College Hospital/Beijing Xiehe Hospital - Xidan Campus, 100032 - Beijing/CN

Resources

This content is available to ESMO members and event participants.

Abstract 194P

Background

Treatment landscape is challenging for patients with advanced esophageal squamous-cell carcinoma (ESCC) who have failed first-line immunotherapy. The potential of combining antiangiogenic therapy with chemotherapy in the treatment of esophageal cancer is well established. Therefore, this study aims to assess the efficacy and safety of combining fruquintinib with S-1 in treating advanced ESCC patients following first-line immunotherapy failure.

Methods

This phase II, single-arm, prospective study consists of dose-finding and dose-expansion phases. The dose-finding phase follows a 3+3 design. Patients received oral fruquintinib (3 mg, 4 mg, 5 mg, d1-d14, q3w) starting at 4 mg qd, in combination with S-1 (40 mg, 50 mg, or 60 mg based on body surface area, bid, d1-d14, q3w) until unacceptable toxicities, progressive disease, or death. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the recommended phase II dose (RP2D), overall response rate (ORR), disease control rate (DCR), and overall survival (OS).

Results

As of June 20th, 2024, ten patients were enrolled in the dose-finding phase and 9 were evaluable, among whom 6 were from fruquintinib 4 mg cohort and 3 from 5 mg cohort. Dose-limiting toxicities (DLTs) were observed in 2 patients at the 5 mg dose level, while no DLTs occurred at 4 mg dose level, and the RP2D was determined. The most common treatment-related adverse events (TRAEs) of any grade were fatigue (8/9), hypertension (4/9), diarrhea (4/9), mucositis (4/9) and abdominal pain (4/9). The most common grade 3 TRAEs were fatigue (3/9) and hypertension (3/9). No grade 4 TRAEs or SAEs were observed. Among the evaluable patients, 1 out of 6 patients from 4 mg cohort and 2 out of 3 patients from 5 mg cohort achieved partial response (PR), yielding an ORR of 33.3% (3/9). The DCR reached 100% (9/9). The median PFS was 5.4 months (95% CI: 2.1 - 10.8), while the median OS reached 10.8 months (95% CI: 2.1 - NA). This trial is still ongoing.

Conclusions

Fruquintinib 4 mg d1-d14, q3w in combination with S-1 was generally well tolerated with potential efficacy in ESCC patients after immunotherapy failure.

Clinical trial identification

NCT05636150.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.